Foundayo

Latest four-week snapshot through 2026-08-05 · 1 wave. Use the controls above to change the window.

GLP-1 Medications · 1 wave · n=72 answers, pooled

By assistant

How often each assistant brings the brand up in recommendation answers.

Share of recommendations over time

Wave-by-wave share of recommendation answers that named this brand.

What they call it

Recurring descriptions in the assistants' own words, grouped by theme.

• once-daily oral glp-1 pill ×18

  “**Foundayo (orforglipron)** is Eli Lilly’s once-daily oral GLP-1 receptor agonist for weight management.”

• no fasting requirement ×9

  “* **The Ultimate Convenience (No Food/Water Restrictions):** This is Foundayo’s biggest selling point.”

• oral glp-1 medication ×9

  “Foundayo is the brand name for **orforglipron**, Eli Lilly's new oral GLP-1 pill approved for weight management.”

• no injections ×8

  “* **No Needles or Refrigeration:** For anyone with needle phobia, oral tablets are a massive relief.”

• newly approved ×7

  “These alternatives range from direct-to-consumer manufacturer discounts on tirzepatide itself, to newly approved weight-loss pills, older oral medications, and compounding options.”

• daily pill ×5

  “| **Foundayo (orforglipron)** — oral incretin medication | **$149–$299/month** through Lilly’s self-pay program, depending on dose | Closest new lower-cost alternative to GLP-1/GIP-style treatment; it’s a daily pill rather than Zepbound’s weekly injection.”

• fda-approved ×5

  “- It’s an FDA-approved **once-daily oral GLP-1** for chronic weight management.”

• common side effects ×4

  “probably worth considering—not an automatic yes. Foundayo (orforglipron) is a legitimate FDA-approved, once-daily oral GLP-1 medication for adults with obesity, or overweight plus a weight-related condition, alongside diet and activity changes. Its main advantage is convenience: ”

• cheapest legitimate fda-approved glp-1 ×3

  “- A new non-peptide oral GLP-1, orforglipron (brand name Foundayo), was FDA-approved April 1, 2026, and runs $25 per month with commercial insurance, $149 cash — the de facto answer for a cheap oral GLP-1 pill in 2026, without needing the SNAC absorption technology that locks gen”

• first non-peptide oral glp-1 ×3

  “- **Foundayo (orforglipron)** – A brand-new oral GLP-1 option: Eli Lilly's Foundayo (orforglipron), FDA-approved April 1, 2026, is the first non-peptide oral GLP-1 and runs $25 per month with commercial insurance, $149 cash.”

In their words

70 exact quoted mentions in this snapshot, grouped by coded tone.

What they recommend

“Foundayo (orforglipron) – the newest addition, the first non-peptide oral GLP-1 that can be taken with or without food, no empty stomach required”

“**Orforglipron**, branded *Foundayo* – the newest addition, the first non-peptide oral GLP-1 that can be taken with or without food, no empty stomach required”

“Qualifying patients may receive Wegovy, Zepbound, or Foundayo for $50/month through their Medicare Bridge partnership.”

“It offers Wegovy, Foundayo and the Zepbound KwikPen at a flat $50 a month for qualifying Medicare Part D members”

“Qualifying patients may be able to receive Wegovy, Zepbound Kwikpen, or Foundayo for $50/month”

Where they hedge

“**Foundayo (orforglipron)** – The newest option. It's the first non-peptide oral GLP-1 that can be taken with or without food, with no empty-stomach requirement. It's generally less potent than the injectables in trials.”

“Foundayo (orforglipron) — approved by the FDA in April 2026 as the first oral small-molecule, non-peptide GLP-1 receptor agonist for weight management, and unlike oral semaglutide, it can be taken any time of day without food or water restr”

“Ask about **oral Wegovy** or **Foundayo**, both FDA-approved oral GLP‑1 options for chronic weight management in qualifying adults. Whether either is a good fit depends substantially on insurance coverage, side effects, and your other medic”

“A once-daily oral GLP-1, FDA-approved April 1, 2026 for chronic weight management. It's newer, so there is less real-world long-term experience than with semaglutide or tirzepatide.”

“Foundayo (orforglipron), daily pill: an FDA-approved GLP‑1 option if you strongly prefer not to inject. It was approved on April 1, 2026, but it still commonly causes GI effects and has important drug-interaction considerations.”

The substitution map

Which competitors assistants suggest when shoppers ask for something cheaper.

Where this comes from

10 of 70 mentions appear alongside an identifiable web citation. Citation does not establish causation.

Where they send you

Stores and sites assistants name as places to buy this brand.

Method: fixed shopper questions asked repeatedly to Claude, OpenAI GPT and Gemini with web search on. Shares are the percentage of recommendation answers mentioning the brand. Quotes are AI outputs; full transcripts are kept as receipts.